Status:
RECRUITING
Understanding immunE-related toXicities by multifACeT Profiling
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Conditions:
Oncology
Eligibility:
All Genders
18+ years
Brief Summary
A prospective observational cohort study of patients undergoing CPI therapy in which translational research is the fundamental aspect of the study.
Detailed Description
The study aims to enroll and obtain samples of investigational interest from 200 patients over a 36-month recruitment period. Blood and/ or stool samples will be taken at baseline, in context of irAE ...
Eligibility Criteria
Inclusion
- Written informed consent
- Age 18 years or older
- Confirmed diagnosis of any form of solid malignancy with a clinical indication and appropriate treatment plan to commence immune checkpoint inhibitor therapy
Exclusion
- Medical or psychological condition that would preclude informed consent
- Planned participation in a drug trial receiving investigational agents
- Subjects who have previously commenced immune checkpoint inhibitor therapy prior to study entry.
- Subjects unable to comply with the study or sample schedule.
Key Trial Info
Start Date :
April 6 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 6 2028
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05331066
Start Date
April 6 2022
End Date
April 6 2028
Last Update
October 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Marsden NHS Foundation Trust
Chelsea, London, United Kingdom, SW3 6JJ